CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Petitprez V et al. Int J Lab Hematol. 2014 Mar 24. doi: 10.1111/ijlh.12216. [Epub ahead of print]. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Martinez-Lopez…
Autophagy in Plasma Cell Pathophysiology. Oliva L et al. Front Immunol. 2014 Mar 12;5:103. eCollection 2014. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Olsen OE et al. Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16. Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++…
Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S et al. Acta Haematol. 2014 Mar 22;132(2):211-219. [Epub ahead of print]. Pathways for blood and bowel cancer patients…
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Korde N et al. Haematologica. 2014 Mar 21. [Epub ahead of print]. Sotatercept in patients with osteolytic lesions of multiple myeloma. Abdulkadyrov KM et al. Br J Haematol. 2014 Mar 21. doi: 10.1111/bjh.12835. [Epub ahead of print]. Evolution of carfilzomib dose and…
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK et al. Biol Blood Marrow Transplant. 2014 Mar 6. pii: S1083-8791(14)00148-7. doi: 10.1016/j.bbmt.2014.02.025. [Epub ahead of print].
Plasma Exchange for Kidney Disease: What Is the Best Evidence?
Hildebrand AM et al. Adv Chronic Kidney Dis. 2014 Mar;21(2):217-227. doi: 10.1053/j.ackd.2014.01.008.
Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients. Suzuki K et al. Jpn J Clin Oncol. 2014 Mar 23. [Epub ahead of print]. Prediction of presence of kidney disease in a general patient population undergoing intravenous iodinated contrast enhanced computed tomography. Moos SI et al. Eur Radiol. 2014…
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.Fouquet G et al. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Mark TM et al. Leuk Lymphoma. 2014 Mar 25. [Epub ahead of…